- Home
- BGI vs SLGL Comparison
BGI vs SLGL Comparison
Compare BGI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- SLGL
- Stock Information
- Founded
- BGI 1879
- SLGL 1997
- Country
- BGI Canada
- SLGL Israel
- Employees
- BGI N/A
- SLGL N/A
- Industry
- BGI
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- SLGL Health Care
- Exchange
- BGI Nasdaq
- SLGL Nasdaq
- Market Cap
- BGI 17.8M
- SLGL 19.3M
- IPO Year
- BGI 2005
- SLGL 2018
- Fundamental
- Price
- BGI $0.90
- SLGL $8.14
- Analyst Decision
- BGI
- SLGL Buy
- Analyst Count
- BGI 0
- SLGL 1
- Target Price
- BGI N/A
- SLGL $40.00
- AVG Volume (30 Days)
- BGI 97.9K
- SLGL 25.4K
- Earning Date
- BGI 07-22-2025
- SLGL 08-15-2025
- Dividend Yield
- BGI N/A
- SLGL N/A
- EPS Growth
- BGI N/A
- SLGL N/A
- EPS
- BGI N/A
- SLGL N/A
- Revenue
- BGI $131,596,265.00
- SLGL $12,103,000.00
- Revenue This Year
- BGI N/A
- SLGL N/A
- Revenue Next Year
- BGI N/A
- SLGL $31.17
- P/E Ratio
- BGI N/A
- SLGL N/A
- Revenue Growth
- BGI 4.01
- SLGL 603.66
- 52 Week Low
- BGI $0.76
- SLGL $3.34
- 52 Week High
- BGI $2.95
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- BGI 46.84
- SLGL 63.80
- Support Level
- BGI $0.84
- SLGL $6.96
- Resistance Level
- BGI $0.98
- SLGL $7.48
- Average True Range (ATR)
- BGI 0.07
- SLGL 0.28
- MACD
- BGI 0.00
- SLGL 0.07
- Stochastic Oscillator
- BGI 38.67
- SLGL 95.88
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.